Association of Fibrinogen with Severity of Stable Coronary Artery Disease in Patients with Type 2 Diabetic Mellitus
Table 1
Baseline demographic, clinical, and laboratory characteristics based on the tertiles of Gensini scores.
Variables
Low (<8; )
Intermediate (8~28; )
High (>28; )
value for trenda
valueb
Risk factors
Age, years
56.7 ± 9.9
60.0 ± 9.4
59.8 ± 8.9
0.008
0.121
Male gender
94 (65.7)
78 (71.6)
90 (74.4)
0.291
0.226
BMI (kg/m2)
25.7 ± 3.3
24.9 ± 2.8
25.7 ± 3.0
0.120
0.447
Current smoking
68 (47.6)
59 (54.1)
70 (57.9)
0.235
0.121
Hypertension
85 (59.4)
77 (70.6)
82 (67.8)
0.145
0.508
Hyperlipidemia
100 (69.9)
88 (80.7)
99 (81.8)
0.039
0.177
PVD
3 (2.1)
3 (2.8)
2 (1.7)
0.847
0.650
Prior stroke
6 (4.2)
3 (2.8)
6 (5.0)
0.690
0.523
Family history of CAD
7 (4.9)
13 (11.9)
17 (14.0)
0.033
0.064
Laboratory test
LVEF (%)
62.8 ± 7.7
63.1 ± 7.4
60.2 ± 9.5
0.014
0.003
NT-pro-BNP (fmol/mL)
661.1 ± 486.8
667.9 ± 485.2
893.5 ± 764.8
0.305
<0.001
hs-CRP (mg/L)
3.1 ± 3.9
2.3 ± 3.5
4.0 ± 4.5
0.006
0.006
Leukocyte (109/L)
6.3 ± 1.5
6.2 ± 1.6
6.8 ± 1.5
0.003
0.001
Platelet count (109/L)
204.5 ± 60.4
192.0 ± 45.8
206.5 ± 55.4
0.098
0.224
Fibrinogen (g/L)
3.0 ± 0.8
2.9 ± 0.7
3.3 ± 0.9
0.000
<0.001
D-dimer (mg/dL)
0.4 ± 0.5
0.4 ± 0.5
0.4 ± 0.6
0.075
0.487
Hemoglobin (g/L)
139.4 ± 15.2
138.3 ± 15.6
137.1 ± 15.6
0.505
0.305
HbA1c (%)
6.4 ± 1.2
6.9 ± 1.6
7.0 ± 1.3
0.000
0.004
FBG
5.6 ± 1.6
6.4 ± 2.7
6.2 ± 1.9
0.009
0.253
Bilirubin (umol/L)
15.3 ± 5.4
15.1 ± 5.6
15.4 ± 7.4
0.969
0.836
ALP (IU/L)
64.2 ± 17.9
61.6 ± 19.1
62.6 ± 17.4
0.517
0.816
AST (IU/L)
19.4 ± 13.3
18.5 ± 9.2
17.4 ± 10.0
0.342
0.185
ALT (IU/L)
31.2 ± 33.3
29.7 ± 21.9
28.7 ± 25.1
0.772
0.554
Creatinine
73.8 ± 15.0
75.6 ± 16.4
78.6 ± 14.9
0.041
0.019
Uric acid
335.6 ± 75.6
323.3 ± 80.8
354.6 ± 77.4
0.009
0.005
Lipid profile
Triglycerides (mmol/L)
1.7 ± 1.0
1.7 ± 0.8
1.8 ± 1.1
0.434
0.230
TC (mmol/L)
4.0 ± 1.0
4.0 ± 0.9
4.1 ± 1.1
0.572
0.360
LDL-C (mmol/L)
2.3 ± 0.9
2.4 ± 0.8
2.5 ± 0.9
0.292
0.121
HDL-C (mmol/L)
1.1 ± 0.3
1.1 ± 0.3
1.0 ± 0.2
0.011
0.009
Lipoprotein (a) (mg/L)
237.7 ± 217.5
190.9 ± 211.2
289.7 ± 283.6
0.008
0.007
apoA (g/L)
1.4 ± 0.3
1.5 ± 0.3
1.4 ± 0.3
0.012
0.057
apoB (g/L)
1.0 ± 0.3
1.0 ± 0.3
1.1 ± 0.3
0.045
0.015
Prior treatment
Aspirin
136 (95.1)
106 (97.2)
118 (97.5)
0.501
0.463
Beta-blocker
103 (72.0)
87 (79.8)
109 (90.1)
0.001
0.001
ACE-I/ARB
27 (18.9)
22 (20.2)
44 (36.4)
0.002
<0.001
Statin
125 (87.4)
109 (100)
116 (95.9)
0.000
0.258
BMI: body mass index; PVD; peripheral vascular disease; CAD: coronary artery disease; LV-FE: left ventricular ejection fraction; NT-pro-BNP: N-terminal pro-brain natriuretic peptide; hs-CRP: high sensitivity C-reactive protein; HbA1c: glycosylated hemoglobin A1c; FBG: fasting blood glucose; ALP: alkaline phosphatase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; ACE-I: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blocker. value obtained from analysis of variance, Kruskal-Wallis test, or chi-squared test; b value for high GS versus nonhigh (low and intermediate) GS.
